文献速递心外重症与机械循环支持

溶栓治疗对耐久性左心室辅助装置泵血栓疗效有限

Limited Efficacy of Thrombolytics for Pump Thrombosis in Durable Left Ventricular Assist Devices.
PubMed 文献 · Ann Thorac Surg · 2020-04-26

单中心回顾性研究分析2004至2018年341例连续流左心室辅助装置(LVAD)植入患者,10.8%(37例)发生泵血栓。其中26例(70.2%)接受初始溶栓治疗,溶栓成功仅11.5%(3例),69.2%(18例)后续需装置更换。泵血栓患者治疗后1年生存率63.1%,1年免于大出血和卒中分别为74.2%和87.2%。结论认为溶栓疗效有限且伴出血/卒中风险,应优化直接泵更换的患者选择。

要点

  • LVAD泵血栓发生率10.8%,溶栓治疗成功率仅11.5%。
  • 溶栓后69.2%患者仍需后续装置更换。
  • 溶栓后1年生存率63.1%,大出血和卒中风险需权衡。

核心结论

  • 溶栓治疗对LVAD泵血栓疗效有限,多数患者需后续泵更换,且伴大出血或卒中风险,应进一步优化直接泵更换的患者选择。

研究设计与样本

  • 单中心回顾性研究,纳入2004至2018年连续流LVAD植入成人患者341例,其中37例(10.8%)发生泵血栓。

主要发现

  • 37例泵血栓患者中,26例(70.2%)接受初始溶栓治疗,5例(13.5%)直接泵更换,6例(16.2%)仅静脉肝素。
  • 溶栓治疗成功率为11.5%(3例),溶栓后早期大出血11.5%(3例),新发卒中7.7%(2例)。
  • 接受溶栓治疗者中69.2%(18例)后续行装置更换。
  • 泵血栓患者治疗后总体生存率30天96.8%、90天78.9%、1年63.1%。
  • 1年免于大出血为74.2%,免于卒中为87.2%。

临床怎么用

  • 对于LVAD泵血栓患者,溶栓治疗成功率低且多数需后续泵更换,临床决策时应综合评估出血和卒中风险,考虑直接泵更换的可能性。

局限性

  • 单中心回顾性研究,样本量较小(泵血栓37例),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study reports a single-center experience with thrombolytics for left ventricular assist device (LVAD) pump thrombosis. METHODS: Adults undergoing continuous-flow LVAD implantation between 2004 and 2018 at a single center were reviewed and those with pump thrombosis were identified. Primary outcomes included 1-year survival and success rates of thrombolytic therapy. Secondary outcomes included posttreatment adverse events, freedom from major bleeding at 1 year, and freedom from stroke at 1-year follow-up. RESULTS: A total of 341 patients underwent LVAD implantation and 10.8% (n = 37) developed pump thrombosis. Of those 37, 26 received initial thrombolytic therapy (70.2%), 5 underwent direct pump exchange (13.5%), and 6 received only intravenous heparin owing to presentation with acute stroke or severe multiorgan failure (16.2%). Successful treatment was achieved in 11.5% of patients receiving thrombolytics (n = 3). Early adverse events after thrombolytic therapy included major bleeding in 11.5% (n = 3) and new stroke in 7.7% (n = 2). Most patients undergoing thrombolytic therapy underwent subsequent device exchange (69.2%; n = 18). Overall survival in patients with pump thrombosis after treatment was 96.8% at 30 days, 78.9% at 90 days, and 63.1% at 1 year. Freedom from major bleeding and stroke at 1 year was 74.2% and 87.2%, respectively. CONCLUSIONS: In this single-center experience of thrombolytics for pump thrombosis in LVAD patients, there was limited efficacy; most patients required subsequent pump exchange. Combined with the risk for major bleeding or stroke with thrombolysis, this underscores the importance of further refining patient selection for direct pump exchange in those presenting with pump thrombosis.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Seese L, Hickey G, Keebler M, et al. Limited Efficacy of Thrombolytics for Pump Thrombosis in Durable Left Ventricular Assist Devices. Ann Thorac Surg. 2020. PMID: 32348739. doi:10.1016/j.athoracsur.2020.03.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。